Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NYSE | Common Stock
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.
The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis.
In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer.
It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
The company was formerly known as Bristol-Myers Company.
Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 26, 24 | 2.07 Increased by +18.29% | 1.63 Increased by +26.99% |
| Apr 25, 24 | -4.40 Decreased by -314.63% | -4.14 Decreased by -6.28% |
| Feb 2, 24 | 1.59 Decreased by -12.64% | 1.43 Increased by +11.19% |
| Oct 26, 23 | 2.00 Increased by +0.50% | 1.76 Increased by +13.64% |
| Jul 27, 23 | 1.75 Decreased by -9.33% | 1.98 Decreased by -11.62% |
| Apr 27, 23 | 2.05 Decreased by -0.49% | 1.97 Increased by +4.06% |
| Feb 2, 23 | 1.82 Decreased by -0.55% | 1.72 Increased by +5.81% |
| Oct 25, 22 | 1.99 Decreased by -0.50% | 1.83 Increased by +8.74% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 11.89 B Increased by +8.44% | 1.21 B Decreased by -37.19% | Increased by +10.18% Decreased by -42.08% |
| Jun 30, 24 | 12.20 B Increased by +8.69% | 1.68 B Decreased by -18.96% | Increased by +13.77% Decreased by -25.43% |
| Mar 31, 24 | 11.87 B Increased by +4.66% | -11.91 B Decreased by -626.57% | Decreased by -100.39% Decreased by -603.14% |
| Dec 31, 23 | 11.48 B Increased by +0.62% | 1.76 B Decreased by -12.86% | Increased by +15.35% Decreased by -13.40% |
| Sep 30, 23 | 10.97 B Decreased by -2.25% | 1.93 B Increased by +20.05% | Increased by +17.58% Increased by +22.81% |
| Jun 30, 23 | 11.23 B Decreased by -5.56% | 2.07 B Increased by +45.88% | Increased by +18.47% Increased by +54.47% |
| Mar 31, 23 | 11.34 B Decreased by -2.67% | 2.26 B Increased by +77.00% | Increased by +19.95% Increased by +81.85% |
| Dec 31, 22 | 11.41 B Decreased by -4.83% | 2.02 B Decreased by -14.76% | Increased by +17.73% Decreased by -10.43% |